Radiotherapy to the Primary Tumour for Patients with Metastatic Prostate Cancer: Practice-Changing Results from STAMPEDE

STAMPEDE is a multi-arm multi-platform randomised controlled trial of treatment for locally advanced, recurrent or hormone-sensitive metastatic prostate cancer, which has energised the UK prostate cancer oncology community. Achieving rapid recruitment, it generated results that have changed systemic therapy practice: docetaxel has been added to lifelong androgen deprivation therapy (ADT) as the standard of care (SoC) in this population, having shown a clinically significant survival advantage [1], and abiraterone is currently being evaluated by the National Institute for Health and Care Excellence (NICE) after showing a comparable survival benefit [2,3].
Source: Clinical Oncology - Category: Radiology Authors: Tags: Editorial Source Type: research